AOTMiT: The Transparency Council will evaluate the diabetes drug

The agenda includes:

1 Prepare a position paper on the evaluation of the drug Trulicity (dulaglutidum) for the indication: type 2 diabetes in patients treated with at least two hypoglycemic drugs, with HbA1c ≥ 7.0%, obesity defined as BMI ≥30 kg/m2 and very high cardiovascular risk defined as:

1) confirmed cardiovascular disease, or

2) damage to other organs manifested by: proteinuria or left ventricular hypertrophy or retinopathy, or

3) the presence of 2 or more major risk factors among those listed below:

- Age ≥ 55 years for men, ≥60 years for women,

- dyslipidemia,

- hypertension,

- smoking.

2 Prepare an opinion on the draft health policy program of the local government unit "Program to support people over 65 in reducing the incidence of cognitive impairment leading to neurodegenerative diseases".

3 Prepare an opinion on the draft health policy program of the local government unit "Health policy program for medical rehabilitation of residents of the Municipality of Kostomloty for 2025- 2029".

Source: AOTMIT